key: cord-0935953-dz9pmc9i
authors: Bacca, Erica; Digaetano, Margherita; Meschiari, Marianna; Franceschini, Erica; Menozzi, Marianna; Cuomo, Gianluca; Mussini, Cristina
title: Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature
date: 2020-11-28
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2020.11.084
sha: b7cc7b30a5d1b50d1f5f16a95ce721bf49a73778
doc_id: 935953
cord_uid: dz9pmc9i

This Mini Review of the literature aimed to assess the role of tocilizumab for the treatment of severe coronavirus disease 2019 (COVID-19). Based on the available scientific evidence, it is not clear to date what is the best therapeutic strategy for the treatment of COVID-19. Since SARS-CoV-2 infection stimulates a vigorous proinflammatory response and may cause the so-called “cytokine storm”, immunomodulator drugs have been investigated as potential treatment for severe COVID-19 pneumonia. Among immunomodulators, tocilizumab, a recombinant humanized monoclonal antibody directed against IL-6 receptor, seems to be promising. An increasing number of clinical trials are exploring the role of tocilizumab in COVID-19, focusing on outcomes like mortality, risk of intensive care unit admission and the need for mechanical ventilation. At the moment, there is no conclusive evidence that tocilizumab would be proper outright in all patients with COVID-19 pneumonia, but some studies suggest that its use may be beneficial in selected categories of patients.

First identified at the end of 2019 in the midst of an outbreak of severe pneumonia in Wuhan City, Hubei Province, China, the new severe acute respiratory coronavirus syndrome 2 (SARS-CoV2) is the causative agent of coronavirus disease 2019 [1, 2] . On January 30, 2020 the WHO declared the COVID-19 epidemic a global health emergency, on March 11, 2020 it was declared a global pandemic (second case after H1N1 influenza in 2009).

The clinical presentation of COVID-19 varies greatly from complete asymptomaticity to severe pneumonia with respiratory failure requiring invasive mechanical ventilation and possibly leading to unfavorable outcome [3] . Although it is difficult to compare mortality rates between different countries due to variable capacity to perform tests and different policies regarding the calculation of deaths, official data seem to show a higher mortality rate in Europe compared to China in the first half of 2020 [4] [5] [6] [7] [8] [9] .

The pathogenesis of the disease is characterized by a first phase of viral replication that can affect both the high and low airways, and a second phase guided by the inflammatory response.

Viral infections induce a proinflammatory response by promoting the production and release of cytokines and chemokines. Both viral surface proteins, viral RNA and intracellular viral proteins have the ability to induce cytokines expression through the activation of signal transduction cascades involving mediators like the IRF family transcription factors (Interferon regulatory factors), NF-κB (nuclear factor kB) and NF-AT (nuclear factor of activated T cells) [10] .

SARS-CoV-2 infection stimulates a vigorous proinflammatory response and may cause an uncontrolled systemic inflammatory response associated with acute respiratory distress J o u r n a l P r e -p r o o f syndrome and a state of hypercoagulability whose pathogenesis is not yet fully understood [11, 12] . In the most severe cases, the so-called "cytokine storm" develops, characterized by increased production of cytokines that produce long-term damage and fibrosis of lung tissues [13] . The spectrum of proinflammatory cytokines and chemokines induced by SARS-CoV2 include TNF-α, CXCL10 and CCL2[14, 15] [ Figure 1 ]. 

Based on the available scientific evidence, it is not clear to date what is the best therapeutic strategy for the treatment of COVID-19 pneumonia, current clinical approaches consider the combination of antivirals and immunomodulatory drugs [16, 17] . Recently published interim results from the Solidarity Therapeutics Trial, supported by the World Health Organization, suggest that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens have little or no effect on overall mortality, initiation of ventilation and duration of hospital stay among COVID-19 hospitalized patients [18] .

Systemic inflammation and hypoxic respiratory failure in COVID-19 are associated with increased release of pro-inflammatory molecules, including C-reactive protein (CRP), Ddimer, ferritin and cytokines [19] . Viral replication induces the synthesis of several proinflammatory cytokines; in particular, the increased production of interleukin 6 (IL-6) by lymphocytes, monocytes, fibroblasts and bronchial epithelial cells has been observed. IL-6 J o u r n a l P r e -p r o o f levels can be considered a major marker of severe systemic inflammatory status in patients with SARS-CoV2 infection.

A model for understanding the pathogenesis of SARS-CoV2-mediated harm has been hypothesized to be hemophagocytic syndrome. Hemophagocytic syndrome is a rare lifethreatening disease characterized by immune hyperactivation that causes fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, hyperferritinemia and hemophagocytosis in the bone marrow, liver, spleen and lymph nodes. It can be either primary or secondary to malignant tumors, autoimmune diseases (SLE, Still's disease) or infections. Viruses that have been associated with the development of a hemophagocytic syndrome include herpetic viruses (particularly EBV, CMV), the human immunodeficiency virus, but also SARS-CoV and MERS-CoV [20, 21] .

In view of the similar hyperinflammatory profile, the use of immunomodulatory therapies has been hypothesized for COVID-19, as well as for hemophagocytic syndrome. Drugs involved in the cytokine cascade, specifically, may reduce the impact of the hyperinflammatory state on lung tissue.

To date, anakinra, an IL-1 receptor antagonist, is approved for rheumatoid arthritis and for the treatment of neonatal-onset multisystem inflammatory disease (NOMID), its possible use in COVID-19 is currently under investigation.

Starting with a first Chinese study [22] , several drugs active on the IL-6 pathway have been evaluated in clinical trials for the treatment of COVID-19. Among the pathway inhibitors are tocilizumab and sarilumab, the latter being a humanized recombinant monoclonal antibody directed against IL-6 receptor currently approved for use only in patients with rheumatoid arthritis. Tocilizumab is a recombinant humanized monoclonal antibody of the IgG1 class directed against both the soluble and the membrane-bound forms of IL-6 receptor.

Tocilizumab is approved for the treatment of severe rheumatoid arthritis, systemic juvenile J o u r n a l P r e -p r o o f idiopathic arthritis, giant cell arteritis and cytokine release syndrome induced by CAR T gene therapies [23] [24] [25] .

Based on the pathogenesis of COVID-19 disease and due to the urgency of this pandemic, the hypothesis was suggested to use tocilizumab off-label for the treatment of patients with severe COVID-19 pneumonia, so that in many centers around the world tocilizumab has become one of the current therapeutic options. Although the regimen for these purposes is not definitively established, in order to obtain appropriate plasma levels based on pharmacokinetic data, tocilizumab is preferably administered intravenously at a dose of 8mg/kg up to a maximum of 800mg in two administrations 12 hours apart. If the intravenous formulation of the drug is unavailable, tocilizumab may also be administered subcutaneously at a dose of 162mg in two simultaneous administrations, for a total of 324 mg [26, 27] .

A review of online databases, namely PubMed and Cochrane Library, was conducted until 22th of October 2020 using the following search terms: 'SARS-CoV2', 'COVID-19', '2019 nCoV' 'coronavirus', 'pneumonia', 'cytokines', 'cytokine storm', 'tocilizumab', 'roactemra', 'sarilumab'.

All studies comparing the clinical efficacy of tocilizumab and its comparators for the treatment of COVID-19 pneumonia were included. Due to the limited scope of the Mini Review, systematic reviews and meta-analyses were not included.

Tocilizumab has been the subject of an increasing number of observational studies, nevertheless, since data from randomized clinical trials are conflicting and most of them J o u r n a l P r e -p r o o f unpublished, current international guidelines from regulatory agencies [28, 29] recommend against the use of tocilizumab except in the context of a clinical trial.

Randomized, double-blind, phase III placebo-controlled trials (REMDACTA, COVACTA, EMPACTA) have been launched to assess the safety and efficacy of tocilizumab in combination with the standard of care in hospitalized patients with severe COVID-19 pneumonia compared to the standard of care plus placebo. ROCHE press release on the subject of the COVACTA study stated that although it showed a reduction in hospitalization time in patients treated with tocilizumab, it did not reach its primary endpoint of clinical improvement, nor its secondary endpoint of mortality reduction [30] . The EMPACTA study conducted in ethnic minorities showed preliminary results meeting the primary endpoint of reduction of mechanical ventilation by day 28, although no difference in mortality was observed at day 28 and other key secondary endpoints were not met as well [31] . The REMDACTA study, which began on May 28 and is also close to completing enrolment, aims to evaluate the safety and efficacy of the combination of tocilizumab and remdesivir in patients hospitalized with severe COVID-19 pneumonia [32] .

Several clinical studies show the efficacy of tocilizumab in reducing inflammation markers and the need for oxygen supplementation, suggesting that its use in patients with severe forms of COVID-19 pneumonia may reduce mortality rates [26, [33] [34] [35] [36] [37] . Among these, a multicenter observational retrospective study conducted in the Hospitals of Modena, Reggio Emilia and Bologna on 544 patients with severe pneumonia has provided evidence that the use of tocilizumab in patients with severe COVID-19 pneumonia reduces the risk of invasive mechanical ventilation and death significantly [26] . In a recent French randomized clinical trial enrolling COVID-19 non-ICU hospitalized patients requiring oxygen support without high-flow oxygen, noninvasive ventilation or mechanical ventilation, the use of tocilizumab was also associated with reduced risk of both invasive and non-invasive mechanical ventilation or death by day 14 [38] . Not least, the STOP-J o u r n a l P r e -p r o o f COVID tocilizumab study, a large observational study conducted on more than 4000 ICU patients across the United States, reports the efficacy of early use of tocilizumab (within 2 days of ICU admission) in reducing 30-day mortality in critically ill patients [39] .

Still, the picture is apparently different in patients with a less severe disease in the attempt to prevent cytokine storm. An Italian randomized multicenter trial aimed at evaluating the efficacy of tocilizumab administered early (within 8 hours of randomization) in patients with moderate COVID-19 pneumonia requiring hospital care, but not invasive or semi-invasive mechanical ventilation procedures, has just ended prematurely. The study was discontinued for futility after an interim evaluation that showed the absence of benefits in treated patients in terms of reduced clinical aggravation or survival, even though mortality was only 3 % in the standard care arm probably due to the strict criteria for inclusion in the study [40] . Likewise, a US-based randomized, double-blind, placebo-controlled trial involving moderately ill hospitalized patients with Covid-19 reported no significant effect on the risk of intubation or death, nor on any of the secondary outcomes examined [41] .

Finally, concerning the possible side-effects of immunomodulatory drugs, while the use of tocilizumab in CAR-T cell therapy apparently do not increase the infection risk [42] , its use in patients with severe COVID-19 pneumonia has been associated with increased infection rate and hepatotoxicity, especially when used in combination with steroids [26, 35, 43, 44] . Other adverse effects include neutropenia and thrombocytopenia.

This topic is worthy of further investigation.

Notoriously, several randomized clinical trials are currently under way, among these the much-awaited Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial would possibly clarify some of the still outstanding issues [45] . This randomized clinical trial aimed at enrolling 15000 in the United Kingdom investigates whether treatment with either Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Convalescent J o u r n a l P r e -p r o o f plasma, Synthetic neutralizing antibodies or Tocilizumab prevents death in patients with COVID-19.

On the basis of all these evidences, even if no clear evidence is available at present, immune-modulatory agents may be promising therapeutic options for the treatment of severe COVID-19. Given the complexity of a scenario so delineated, the timing of tocilizumab administration therefore appears crucial: although the use of tocilizumab has not been shown to be beneficial outright in all patients with COVID-19 pneumonia, it is likely to maximize its positive effects in selected categories of patients with severe clinical manifestation (characterized by parameters such as peripheral oxygen saturation below 93%, a PaO2/FiO2 ratio below 300 and/or a worsening of more than 30% in 24 hours) sustained by a hyperinflammatory profile (demonstrated by high values of CRP, LDH, ferritin, IL6). More precise identification of predictive factors for disease progression may help to identify the best time for treatment with tocilizumab.

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis

WHO Coronavirus Disease

Estimating mortality from COVID-19

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV

Admitted to ICUs of the Lombardy Region

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Molecular Pathways in Virus-Induced Cytokine Production, Microbiol

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia?

SARS-CoV-2: a storm is raging

Cytokine storm in aged people with CoV-2: possible role of vitamins as therapy or preventive strategy

Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease

COVID-19: combining antiviral and anti-inflammatory treatments

A.R. for the C. and I. of T.A. as the members of the Writing Committee, Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Anunciacion-Llunell, F. Miró-Mur, Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review

Tocilizumab treatment in COVID-19: A single center experience

Interleukin-6 inhibitors in the treatment of rheumatoid arthritis

Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

Trial of Tocilizumab in Giant-Cell Arteritis

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects

COVID-19) treatment guidelines., COVID-19 Treat

Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia

Roche's phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients -An Observational Study

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19

CORIMUNO-19 Collaborative Group, Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

STOP-COVID Investigators, Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in

Two fatal cases of acute liver failure due to HSV-1 infection in COVID-19 patients following immunomodulatory therapies

Randomised Evaluation of COVID-19 Therapy -Full Text View -ClinicalTrials.gov

All third-party financial support for the work in the submitted manuscript

All financial relationships with any entities that could be viewed as relevant to the general area of the submitted manuscript

All sources of revenue with relevance to the submitted work who made payments to you, or to your institution on your behalf

Any other interactions with the sponsor of outside of the submitted work should also be reported. (5) Any relevant patents or copyrights (planned, pending, or issued)

Any other relationships or affiliations that may be perceived by readers to have influenced, or give the appearance of potentially influencing, what you wrote in the submitted work. As a general guideline

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The figure was created with BioRender.com.